ClinicalTrials.gg
Not yet recruitingNCT07622992OPTI-OAGBUpdated Sep 10, 2026

Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery

An observational study in Obesity (BMI > 35) and Diabetes Mellitus, Obesity (BMI > 35) and Dyslipemia and Obesity (BMI > 35) and High Blood Pressure, sponsored by Mario Musella MD. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Mario Musella MD · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
96
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 342 studies in Obesity with a site in Italy — 99 open to participants now, 118 under way, 28 of them phase 3. Obesity · Italy.

Planned enrollment
67th of 112
96 · median 120
Started
2027
with 1 other
Observational
112 of 342
37 open now
Primary completion
2029-07
later than 105 of 117 live
Registered
325th of 342
by date

Among the 342 studies in Obesity with a site in Italy, this one is the 67th largest by planned enrollment of the 112 observational ones that give a count, is one of 2 that started in 2027, is one of 112 observational ones, reaches primary completion later than 105 of the 117 other live ones, and was the 325th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

99 of the 342 studies in Obesity with a site in Italy are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Obesity with a site in Italy, or all of them as a file.
02

Study summary

This study compares three preoperative strategies before one anastomosis gastric bypass(OAGB) for severe obesity. Participants will be assigned to receive either tirzepatide medication for 60 days, a ketogenic diet for 4 weeks, or standard care before surgery. The main goal is to determine which approach leads to the best weight loss one year after surgery. The study will also evaluate safety, surgical outcomes, and improvement of obesity-related health conditions such as diabetes, high blood pressure, and sleep apnea.

Read the detailed description

Obesity remains a major global health challenge. Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity, but outcomes vary significantly among patients. This study investigates whether preoperative optimization with pharmacological treatment (tirzepatide) or dietary intervention (ketogenic diet) can improve long-term weight loss compared to proceeding directly to surgery without specific preoperative preparation.

Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown remarkable efficacy in weight reduction trials. The ketogenic diet is a very-low-calorie approach that induces rapid weight loss while preserving lean body mass. However, no randomized trial has directly compared these strategies for preoperative optimization in MBS candidates.

This multicenter randomized controlled trial will enroll 96 patients with severe obesity (BMI 45-55 kg/m²) scheduled for One Anastomosis Gastric Bypass (OAGB). Participants will be randomized 1:1:1 to three arms: (A) tirzepatide treatment for 60 days with dose escalation (2.5 mg → 5 mg → 7.5 mg weekly subcutaneous injections); (B) supervised ketogenic diet for 4 weeks (700 kcal/day with less than 50g carbohydrates); or (C) standard preoperative care without specific intervention.

All participants will undergo standardized OAGB surgery performed by experienced surgeons.

The primary endpoint is percentage of total weight loss at 12 months post-surgery. Secondary endpoints include perioperative outcomes (operative time, complications, hospital stay), resolution of obesity-related comorbidities (diabetes, hypertension, dyslipidemia, sleep apnea), nutritional status.

Randomization will be stratified by baseline BMI category, presence of type 2 diabetes, and participating center to ensure balance across important prognostic factors. Follow-up visits will occur at 30 days, 3 months, 6 months, and 12 months post-surgery with comprehensive clinical and laboratory assessments.

This study will provide crucial evidence to guide clinical decision-making regarding optimal preoperative management strategies for patients undergoing bariatric surgery, addressing the balance between potential benefits of preoperative weight loss and surgical safety.

03

Conditions studied

  • Obesity (BMI > 35) and Diabetes Mellitus
  • Obesity (BMI > 35) and Dyslipemia
  • Obesity (BMI > 35) and High Blood Pressure

Keywords

  • Bariatric Surgery
  • OAGB
  • Tirzepatide
  • Ketogenic Diet
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients between 18 to 65 years, with Body Mass Index (BMI) between 40 and 55 kg/m² at screening visit. The patients must be eligible for bariatric surgery according to current international guidelines (IFSO 2022) with documented failure of conservative weight loss attempts. Patients enrolled need to have at least one obesity-related comorbidity and the ability to understand study procedures and provide written consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 65 years at enrollment
  • (BMI) between 40 and 55 kg/m² at screening visit
  • Appropriate candidates for bariatric surgery according to current international guidelines (IFSO 2022) with documented failure of conservative weight loss attempts
  • Presence of at least one obesity-related comorbidity: Type 2 Diabetes Mellitus ( at least 6.5%, fasting plasma glucose at least 126 mg/dL, 2-hour OGTT glucose at least 200 mg/dL, or use of antidiabetic medications); Hypertension (systolic BP at least 140 mmHg or diastolic BP at least 90 mmHg, or use of antihypertensive medications); Dyslipidemia (total cholesterol at least 200 mg/dL, LDL-C at least 130 mg/dL, HDL-C less than 40 mg/dL for men or less than 50 mg/dL for women, triglycerides at least 150 mg/dL, or use of lipid-lowering medications); Obstructive Sleep Apnea Syndrome (AHI at least 15 events/hour or AHI 5-14 with symptoms requiring treatment)
  • Ability to understand study procedures and provide written
  • Demonstrated ability and willingness to adhere to study protocol requirements including preoperative interventions and postoperative follow-up visits
  • No use of GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists within 12 months prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • History of any prior bariatric procedure or major upper gastrointestinal surgery that could confound outcomes or increase surgical risk
  • Severe uncontrolled psychiatric disorders including active psychosis, severe depression with suicidal ideation, active substance abuse, or eating disorders (other than binge eating disorder) that could impair protocol adherence or capacity
  • Current pregnancy, lactation, or planning pregnancy within 18 months of enrollment (women of must use effective throughout study period)
  • to tirzepatide for patients potentially randomized to Arm A: personal or family history of medullary thyroid carcinoma; Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); history of pancreatitis; severe gastrointestinal disease (inflammatory bowel disease, gastroparesis); known to tirzepatide or
  • Contraindications to ketogenic diet for patients potentially randomized to Arm B: chronic kidney disease ( less than 30 mL/min/1.73m²); severe hepatic insufficiency ( C); active gallbladder disease; history of kidney stones; porphyria; carnitine deficiency or other metabolic disorders
  • Current or recent (within 5 years) at any stage
  • Severe cardiopulmonary disease including recent myocardial infarction (less than 6 months), unstable angina, heart failure ( class III-IV), severe pulmonary hypertension, or other conditions representing absolute contraindications to general anesthesia
  • Systemic infection requiring treatment at time of enrollment
  • Inability or unwillingness to attend required follow-up visits, language barriers preventing adequate communication, or any condition that would compromise protocol compliance
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
96 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ketogenic Diet 4 Weeks

    Participants undergo supervised very-low-calorie ketogenic diet (VLCKD) for 4 weeks immediately before OAGB surgery.

  • Standard Care Control

    Participants undergo standard preoperative preparation without specific medical or dietary intervention. Includes standard multidisciplinary evaluation (surgeon, dietitian, psychologist, anesthesiologist), general nutritional counseling, encouragement to maintain current weight and avoid weight gain, no structured calorie restriction or specific dietary protocol, and no GLP-1 receptor agonist or weight loss pharmacotherapy

  • Tirzepatide 60 Days

    Participants receive tirzepatide (Mounjaro®) subcutaneously once weekly for 60 days prior to OAGB surgery following dose escalation protocol: Weeks 1-4: 2.5 mg weekly; Weeks 5-8: 5 mg weekly; Week 9 (if tolerated): 7.5 mg weekly. Tirzepatide discontinued 7 days before surgery.

This study also gives Tirzepatide. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Percentage of Total Weight Loss at 1 Year Post-Surgery

    The primary endpoint is the percentage of total weight loss (%TWL) measured at 12 months after bariatric surgery. %TWL is calculated as: \[(Baseline Weight - Weight at 12 months) / Baseline Weight\] × 100

    Time frame: 1 year

Secondary outcomes

  1. Percentage of Excess Weight Loss at 1 Year

    Percentage of excess weight loss (%EWL) calculated as: \[(Baseline Weight - Weight at 12 months) / (Baseline Weight - Ideal Body Weight)\] × 100, where Ideal Body Weight is calculated using the Devine formula

    Time frame: 1 year

  2. Absolute Weight Loss at 1 Year

    Absolute weight loss measured in kilograms (kg), calculated as the difference between baseline weight (at randomization) and weight at 12 months post-surgery

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Study Protocol and results

Supporting information: Study protocol

Time frame: From 2029 for 1 year

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jul 2029, 30 months later.

Of 793 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 30 months is below that.

Counting every sponsor, half of 839 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 3, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jul 1, 2029
CompletionEst.
Dec 1, 2029
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07622992
Lead sponsor
Mario Musella MD
Responsible party
Mario Musella MD (Prof., Federico II University) — Sponsor-investigator
First posted
Jun 3, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jul 1, 2029 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Sep 10, 2026

Study contacts

Mario Musella Prof, MD
Contact
mario.musella@unina.it
0039 0817462880

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion